MCID: ACT027
MIFTS: 60

Acute Pancreatitis

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Pancreatitis

MalaCards integrated aliases for Acute Pancreatitis:

Name: Acute Pancreatitis 12 74 36 29 54 6 15 62 17 71 32
Pancreatitis, Acute Necrotizing 71
Acute Necrotizing Pancreatitis 12
Pancreatitis Necrotizing 12
Necrotizing Pancreatitis 54
Pancreatitis 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2913
KEGG 36 H01681
ICD9CM 34 577.0
MeSH 44 D010195
NCIt 50 C95437
SNOMED-CT 67 39726008
ICD10 32 K85 K85.9
UMLS 71 C0001339 C0267941

Summaries for Acute Pancreatitis

KEGG : 36 Acute pancreatitis ranges from a mild, self- limiting disease to a life-threatening condition with multiple organ failure. Abdominal pain is the predominant symptom. Nausea and vomiting may accompany the pain. Patients frequently have a low-grade fever, tachycardia, and hypotension. The most common causes of acute pancreatitis are alcohol abuse and gallstones. The currently accepted pathogenic mechanism includes autodigestion and acute inflammation of the pancreas by the activation of proteases of the pancreas and acute inflammatory cells. Severe acute pancreatitis is defined by the presence of organ failure persisting beyond 48 hour. Organ failure that develops during the early phase is set in motion by the activation of cytokine cascades resulting in systemic inflammatory response syndrome (SIRS). Although effective therapies for acute pancreatitis are still limited, protease inhibitors have been considered to be a potential treatment to inhibit the pancreatic inflammation.

MalaCards based summary : Acute Pancreatitis, also known as pancreatitis, acute necrotizing, is related to mikulicz disease and familial lipoprotein lipase deficiency. An important gene associated with Acute Pancreatitis is CPB1 (Carboxypeptidase B1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Salivary secretion. The drugs Cefoperazone and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and kidney, and related phenotype is homeostasis/metabolism.

PubMed Health : 62 About acute pancreatitis: Acute pancreatitis is an inflammation of the pancreas that typically causes very sudden and very severe stomach ache. The most common causes are gallstones and excessive alcohol consumption. Acute pancreatitis can have serious complications, so it is typically treated in the hospital. Most of the time it passes without any serious problems developing in about one to two weeks. But in more severe cases of pancreatitis, treating the complications may take up to several months. Complications of pancreatitis can be fatal.

Wikipedia : 74 Acute pancreatitis (AP) is a sudden inflammation of the pancreas. Causes in order of frequency include:... more...

Related Diseases for Acute Pancreatitis

Diseases in the Pancreatitis family:

Pancreatitis, Hereditary Autoimmune Pancreatitis
Acute Pancreatitis Prss1-Related Hereditary Pancreatitis
Autoimmune Pancreatitis Type 2 Autoimmune Pancreatitis Type 1

Diseases related to Acute Pancreatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1613)
# Related Disease Score Top Affiliating Genes
1 mikulicz disease 32.0 SPINK1 IL10 CRP
2 familial lipoprotein lipase deficiency 32.0 PNLIP LPL APOC2
3 hyperlipoproteinemia, type i 31.7 PNLIP LPL APOC2
4 compartment syndrome 31.7 IL6 GPT CRP
5 glucagonoma 31.7 SST SCT
6 cholelithiasis 31.6 SST GPT CRP CCK
7 adult respiratory distress syndrome 31.6 MPO IL6 IL10 ELANE CXCL8
8 toxic shock syndrome 31.6 IL6 IL10 CXCL8 CRP
9 purpura 31.5 IL6 IL10 CRP
10 ileus 31.5 SST IL6 IL10 CRP CCK
11 choledocholithiasis 31.4 GPT CRP CCK
12 obstructive jaundice 31.4 IL6 GPT CXCL8 CRP
13 biliary tract disease 31.4 IL6 GPT CRP CCK
14 peritonitis 31.4 MPO IL6 IL10 ELANE CXCL8 CRP
15 ulcerative colitis 31.4 MPO IL6 IL10 CXCL8 CRP
16 cholangitis 31.3 SST MPO IL6 IL10 GPT CXCL8
17 crohn's disease 31.3 MPO IL6 IL10 CXCL8 CRP
18 respiratory failure 31.3 MPO IL6 IL10 GPT ELANE CXCL8
19 viral hepatitis 31.3 IL6 IL10 GPT CRP
20 acute cholangitis 31.3 IL6 GPT CRP
21 alcoholic pancreatitis 31.3 SPINK1 SCT REG3A LPL CPB1 CCK
22 pulmonary edema 31.3 IL10 CXCL8 CRP
23 vasculitis 31.3 MPO IL6 ELANE CRP
24 chickenpox 31.2 IL6 IL10 CRP
25 disseminated intravascular coagulation 31.2 IL6 IL10 GPT ELANE CRP
26 mumps 31.2 IL6 IL10 CXCL8
27 hyperglycemia 31.2 SST LPL IL6 CCK
28 appendicitis 31.2 MPO IL6 IL10 CXCL8 CRP
29 gastroenteritis 31.2 IL6 IL10 CXCL8 CRP
30 pancreatic agenesis 1 31.2 SPINK1 SCT PNLIP
31 intestinal obstruction 31.2 IL6 GPT CRP
32 leptospirosis 31.1 IL6 IL10 CXCL8 CRP
33 gastric ulcer 31.1 SST IL6 CXCL8
34 duodenal obstruction 31.1 SPINK1 SCT CRP
35 chronic kidney disease 31.1 MPO LPL IL6 IL10 CXCL8 CRP
36 severe acute respiratory syndrome 31.1 IL6 IL10 CXCL8 CTSB CRP
37 bacterial infectious disease 31.0 IL6 IL10 ELANE CXCL8 CRP
38 pericardial effusion 31.0 IL6 GPT CRP
39 exanthem 31.0 IL6 IL10 GPT CXCL8 CRP
40 pancreatitis 31.0 VMP1 TMPRSS15 SST SPINK1 SCT REG3A
41 peptic ulcer disease 31.0 SST SCT IL10 CXCL8
42 aortic aneurysm, familial abdominal, 1 30.9 IL6 IL10 ELANE CXCL8 CRP
43 portal hypertension 30.9 SST GPT CXCL8
44 proteasome-associated autoinflammatory syndrome 1 30.9 MPO IL6 IL10 ELANE CXCL8 CRP
45 typhoid fever 30.9 IL6 GPT CRP
46 pericarditis 30.9 IL6 CXCL8 CRP
47 hereditary angioedema 30.9 MPO ELANE CRP
48 brucellosis 30.8 MPO IL6 IL10 CXCL8 CRP
49 glucose intolerance 30.8 SST LPL IL6 GPT CRP
50 type 1 diabetes mellitus 30.8 SST IL6 IL10 CXCL8 CRP

Comorbidity relations with Acute Pancreatitis via Phenotypic Disease Network (PDN): (show all 34)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Vascular Insufficiency of Intestine
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Atrophic Gastritis
Biliary Tract Disease Cholangitis
Cholecystitis Cholestasis
Deficiency Anemia Duodenitis
Esophageal Disease Esophagitis
Gallbladder Disease Heart Disease
Hepatitis Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypothyroidism
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Liver Disease
Pancreatic Agenesis 1 Pancreatic Cancer
Pancreatitis, Hereditary Paralytic Ileus
Postcholecystectomy Syndrome Protein-Energy Malnutrition
Respiratory Failure Strawberry Gallbladder

Graphical network of the top 20 diseases related to Acute Pancreatitis:



Diseases related to Acute Pancreatitis

Symptoms & Phenotypes for Acute Pancreatitis

MGI Mouse Phenotypes related to Acute Pancreatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.53 APOC2 CCK CPB1 CRP CTSB ELANE

Drugs & Therapeutics for Acute Pancreatitis

PubMed Health treatment related to Acute Pancreatitis: 62

No treatment is available for dealing with the root cause of pancreatitis . But there are a number of options for reducing strain on the pancreas and relieving symptoms. Because fluid levels can drop due to acute pancreatitis , the first step is to prevent dehydration by using infusion therapy . A hollow needle inserted in an arm vein is used to release a solution into the bloodstream. Medication is used to provide relief from pain, nausea and vomiting . Stronger painkillers such as opioids are sometimes needed, and they may make you feel drowsy or light-headed. Solid foods are avoided until the pain recedes and appetite returns to give the pancreas a chance to recuperate. In mild cases of pancreatitis it is sometimes possible to return to eating solid foods after just a few days. If the symptoms last longer, artificial feeding may be necessary to supply your body with enough nutrients . If the pancreatitis is caused by gallstones , the stones may need to be removed using endoscopic retrograde cholangiography. After treatment the gallbladder is surgically removed to prevent further episodes.

Drugs for Acute Pancreatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 739)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
2
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
5
Iron Approved Phase 4 7439-89-6 23925 29936
6
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
10
Glimepiride Approved Phase 4 93479-97-1 3476
11
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
12
Meperidine Approved Phase 4 57-42-1 4058
13
Etomidate Approved Phase 4 33125-97-2 36339 667484
14
Simethicone Approved Phase 4 8050-81-5
15
Titanium dioxide Approved Phase 4 13463-67-7
16
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Insulin glargine Approved Phase 4 160337-95-1
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
22
Insulin glulisine Approved Phase 4 207748-29-6
23
Glycerol Approved, Investigational Phase 4 56-81-5 753
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
26
Levodopa Approved Phase 4 59-92-7 6047
27
Thrombin Approved, Investigational Phase 4
28
Protein C Approved Phase 4
29
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
31
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
32
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
33
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
37
Morphine Approved, Investigational Phase 4 57-27-2 5288826
38
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
39
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
40
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
41
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
42
Resveratrol Investigational Phase 4 501-36-0 445154
43
Nimotuzumab Investigational Phase 4 780758-10-3, 828933-61-3
44
Polygeline Experimental Phase 4 66455-30-9
45
Thymalfasin Investigational Phase 4 62304-98-7
46 Disinfectants Phase 4
47 Sulperazone Phase 4
48 Soybean oil, phospholipid emulsion Phase 4
49 Fat Emulsions, Intravenous Phase 4
50 Fibrin Tissue Adhesive Phase 4

Interventional clinical trials:

(show top 50) (show all 3189)
# Name Status NCT ID Phase Drugs
1 Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
2 Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis Unknown status NCT01992198 Phase 4 cefoperazone + metronidazole;Somatostatin;Meropenem
3 Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Unknown status NCT02691598 Phase 4 Infusion
4 Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution Unknown status NCT01376817 Phase 4 Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;Fat emulsion with MCT and LCT
5 Randomized, Controlled, Open-label Trial of Intravenous Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis. Unknown status NCT03501680 Phase 4 Insulin
6 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
7 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
8 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Unknown status NCT03642093 Phase 4
9 Random Comparing Study on Two Different EUS-guided Pseudocyst Drainage Methods--Modified Naso-pancreatic Tube Drainage and Stents Drainage Unknown status NCT01585662 Phase 4
10 Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal: A Prospective Study. Unknown status NCT03082469 Phase 4
11 Effect Observation Study of COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis Unknown status NCT02964403 Phase 4 Cox-2;Indomethacin
12 Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis Unknown status NCT03708458 Phase 4 indomethacin suppository;N-acetylcysteine (NAC)
13 Randomized, Controlled, Multicenter Studies of the Effects of Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Unknown status NCT03342807 Phase 4 Insulin
14 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
15 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
16 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
17 Prevention for Surgical Site Infection After Pancreatic Resection Unknown status NCT00661648 Phase 4
18 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
19 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
20 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
21 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Unknown status NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
22 Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT Unknown status NCT02621541 Phase 4
23 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
24 APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial Completed NCT01017107 Phase 4 Activated protein C
25 Studie Naar De Effectiviteit Van Ursodeoxycholzuur Ter Preventie Van Galsteen-Gerelateerde Klachten Bij patiënten in Afwachting Van Een Cholecystectomie Completed NCT00161083 Phase 4 ursodeoxycholic acid
26 Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Completed NCT00999232 Phase 4 Erythromycin;Placebo
27 The Impact of Early Enteral Nutrition on the Clinical Outcomes of Severe Acute Pancreatitis Patients: A Randomized Control Trial Completed NCT00995098 Phase 4
28 A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis Completed NCT00061438 Phase 4 meropenem
29 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
30 Enteral Nutrition for Treatment of Acute Pancreatitis - a Prospective, Randomized Clinical Trial Completed NCT01965873 Phase 4
31 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
32 Imipenem Prophylaxis of Infectious Complications in Patients With Acute Pancreatitis Completed NCT02897206 Phase 4 Imipenem;Placebo
33 Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis Completed NCT00786929 Phase 4 Conservative treatment
34 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
35 A Multi-Center, Prospective, Randomized Study Comparing Removable, Self-Expanding Metal Stents to Plastic Stents for the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis Completed NCT01543256 Phase 4
36 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
37 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
38 Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
39 Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis Completed NCT00318994 Phase 4 Meropenem
40 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
41 Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
42 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study Completed NCT01744847 Phase 4
43 Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial Completed NCT01784445 Phase 4 Ceftazidime
44 A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation Completed NCT01186562 Phase 4 Sitagliptin;Placebo
45 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
46 A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation Completed NCT01408264 Phase 4
47 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
48 Prospective Study for the Effects of High Dose Pancreatic Enzyme Replacement Therapy on Body Weight, Quality of Life, and Nutritional Assessment After Pancreatoduodenectomy Completed NCT02127021 Phase 4 Norzyme® 40000 IU;Placebo
49 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
50 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed NCT02973477 Phase 4 Dapagliflozin;Glimepiride

Search NIH Clinical Center for Acute Pancreatitis

Cochrane evidence based reviews: pancreatitis

Genetic Tests for Acute Pancreatitis

Genetic tests related to Acute Pancreatitis:

# Genetic test Affiliating Genes
1 Acute Pancreatitis 29

Anatomical Context for Acute Pancreatitis

MalaCards organs/tissues related to Acute Pancreatitis:

40
Pancreas, Liver, Kidney, Pancreatic Islet, Neutrophil, T Cells, Bone Marrow

Publications for Acute Pancreatitis

Articles related to Acute Pancreatitis:

(show top 50) (show all 24215)
# Title Authors PMID Year
1
Obesity and the risk of severe acute pancreatitis. 54 61
20485254 2010
2
Different profiles of cytokine expression during mild and severe acute pancreatitis. 54 61
20397261 2010
3
Transgenic expression of pancreatic secretory trypsin inhibitor-1 rescues SPINK3-deficient mice and restores a normal pancreatic phenotype. 54 61
20110462 2010
4
-651C/T promoter polymorphism in the CD14 gene is associated with severity of acute pancreatitis in Japan. 61 54
19997857 2010
5
New diagnostic criteria of acute pancreatitis. 54 61
20012328 2010
6
Connections between genetics and clinical data: Role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic pancreatitis. 54 61
19844201 2010
7
[Influence of integrated traditional Chinese and Western medicine therapy on serum resistin levels in patients with severe acute pancreatitis: a randomized controlled trial]. 54 61
20015433 2009
8
Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. 54 61
20072945 2009
9
Pathogenic role of myeloperoxidase in acute pancreatitis. 61 54
20007081 2009
10
[Effect of qingyi decoction in treating severe acute pancreatitis and its impacts on blood level of tumor necrosis factor-alpha, interleukin-6 and inteleukin-8]. 61 54
20214338 2009
11
Role of pancreatitis-associated protein 1 on oxidative stress-induced cell death of pancreatic acinar cells. 54 61
19723102 2009
12
Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis. 54 61
19486901 2009
13
Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. 61 54
19214137 2009
14
Microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene is associated with susceptibility to acute pancreatitis in Japan. 54 61
19280717 2009
15
A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers. 61 54
19041716 2009
16
Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. 54 61
19007927 2009
17
[The study of the relationship between interleukin gene polymorphism and the morbidity of patients with acute pancreatitis]. 61 54
19220961 2009
18
Pancreatitis-associated protein is related closely to neoplastic proliferative activity in patients with colorectal carcinoma. 61 54
19051257 2009
19
Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. 54 61
20110745 2009
20
Acute pancreatitis as a model of SIRS. 61 54
19273184 2009
21
Significance of endothelial molecular markers in the evaluation of the severity of acute pancreatitis. 54 61
19319639 2009
22
Serum profiles of C-reactive protein, interleukin-8, and tumor necrosis factor-alpha in patients with acute pancreatitis. 61 54
20130823 2009
23
Activated protein C-protein C inhibitor complex, activation peptide of carboxypeptidase B and C-reactive protein as predictors of severe acute pancreatitis. 54 61
19684435 2009
24
Acute pancreatitis in a girl with panhypopituitarism due to craniopharyngioma on growth hormone treatment. A combination of risk factors. 61 54
19506396 2009
25
Icam-1 and acute pancreatitis complicated by acute lung injury. 54 61
19129609 2009
26
[Relationship between acute pancreatitis and systemic inflammation response syndrome in children]. 54 61
19102837 2008
27
[Interleukin 18 (IL-18) and other immunological parameters as markers of severity in acute pancreatitis]. 54 61
19222336 2008
28
Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography. 61 54
19114324 2008
29
Morbimortality indicators in severe acute pancreatitis. 61 54
18981549 2008
30
Implication of interleukin 18 and intercellular adhesion molecule (ICAM)-1 in acute pancreatitis. 54 61
19102398 2008
31
Molecular basis for pancreatitis. 61 54
19122498 2008
32
The SPINK1 N34S variant is associated with acute pancreatitis. 61 54
18617776 2008
33
Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. 61 54
18720532 2008
34
Pancreatitis-associated protein 2 modulates inflammatory responses in macrophages. 54 61
18641332 2008
35
The effects of a new human leukocyte elastase inhibitor (recombinant guamerin) on cerulein-induced pancreatitis in rats. 61 54
18486906 2008
36
Interleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice. 54 61
18515422 2008
37
[Acute pancreatitis secondary to hypertriglyceridemia - a report of two cases]. 54 61
18752369 2008
38
Ritonavir and disulfiram may be synergistic in lowering active interleukin-18 levels in acute pancreatitis, and thereby hasten recovery. 61 54
18469453 2008
39
Acute pancreatitis. 54 61
18388680 2008
40
Is there correlation between pancreatic enzyme and radiological severity in acute pancreatitis? 54 61
18416469 2008
41
[Utility of endoscopic ultrasonography in the etiological diagnosis of patients with acute idiopathic pancreatitis]. 54 61
18405484 2008
42
Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells. 61 54
18160487 2008
43
Protease activation, pancreatic leakage, and inflammation in acute pancreatitis: differences between mild and severe cases and changes over the first three days. 54 61
18849642 2008
44
Monocyte chemoattractant protein 1, active carboxypeptidase B and CAPAP at hospital admission are predictive markers for severe acute pancreatitis. 54 61
18235216 2008
45
Risk factors for recurrent acute alcohol-associated pancreatitis: a prospective analysis. 54 61
18415757 2008
46
[Pancreatitis in pregnant women]. 61 54
18720707 2008
47
TLR and MBL gene polymorphisms in severe acute pancreatitis. 61 54
18288881 2008
48
Sphincter of Oddi dysfunction and pancreatitis. 61 54
18081221 2007
49
A novel complex deletion-insertion mutation mediated by Alu repetitive elements leads to lipoprotein lipase deficiency. 54 61
17706445 2007
50
Interleukin-18: a pro-inflammatory cytokine that plays an important role in acute pancreatitis. 61 54
17907957 2007

Variations for Acute Pancreatitis

Expression for Acute Pancreatitis

Search GEO for disease gene expression data for Acute Pancreatitis.

Pathways for Acute Pancreatitis

Pathways related to Acute Pancreatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 MPO IL6 ELANE CXCL8
2
Show member pathways
11.79 SST SCT PNLIP CPB1 CCK
3 11.67 SST IL6 IL10 CXCL8
4 11.51 IL6 IL10 CXCL8
5 11.24 IL6 IL10 CXCL8
6 11.19 IL6 IL10 CXCL8
7 11.11 MPO IL6 ELANE
8 10.28 SCT CCK
9 10.08 IL6 CXCL8 CRP

GO Terms for Acute Pancreatitis

Cellular components related to Acute Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 SST SPINK1 SCT REG3A PNLIP MPO
2 extracellular space GO:0005615 9.58 SST SPINK1 SCT REG3A PNLIP MPO

Biological processes related to Acute Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of chemokine production GO:0032682 9.43 IL6 ELANE
2 response to molecule of bacterial origin GO:0002237 9.4 IL10 CXCL8
3 very-low-density lipoprotein particle remodeling GO:0034372 9.37 LPL APOC2
4 retinoid metabolic process GO:0001523 9.33 PNLIP LPL APOC2
5 chylomicron remodeling GO:0034371 9.32 LPL APOC2
6 negative regulation of lipid storage GO:0010888 9.26 IL6 CRP
7 response to yeast GO:0001878 8.96 MPO ELANE
8 acute-phase response GO:0006953 8.8 REG3A IL6 CRP

Molecular functions related to Acute Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.02 TMPRSS15 ELANE CTSB CPB1 CPA6

Sources for Acute Pancreatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....